EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug–Drug Interaction Study in Patients With Non‐Hodgkin Lymphoma

Masaya Tachibana iD, Steven Horwitz iD, Eric Jacobsen iD, Francine Foss iD, Pamela Allen iD, Pierluigi Porcu iD, Tatyana Feldman iD, Jia Ruan iD, Jonathan E Brammer iD, Jie Wang iD, Shinichi Inaba iD, Yuka Iko iD und 5 weitere

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70330 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Masaya Tachibana und 16 weiteren Autor:innen. Beteiligte Einrichtung: Daiichi Sankyo Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Digoxin, Midazolam, Lymphoma, Non-Hodgkin, Sulfonamides. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Valemetostat tosylate (valemetostat) is an oral, potent, dual inhibitor of enhancer of zeste homolog (EZH)2/1, under investigation in non‐Hodgkin lymphomas (NHLs) and solid tumors. In vitro, it inhibits cytochrome P450 3A (CYP3A) and P‐glycoprotein (P‐gp) when combined with sensitive CYP3A or P‐gp substrates. This drug–drug interaction (DDI) sub‐study is part of the phase 1 trial of valemetostat monotherapy (DS3201‐A‐J101; NCT02732275), assessing the effect of valemetostat on the pharmacokinetics (PK) of sensitive CYP3A and P‐gp substrates midazolam and digoxin, respectively, in patients with relapsed or refractory NHL, and its safety and efficacy. Patients received two simultaneous single doses of midazolam and digoxin: once alone and once concomitantly with a daily 200 mg valemetostat dose in a 28‐day cycle. Of 24 enrolled patients, 15 and 16 were evaluable for PK analyses of midazolam and digoxin, respectively. Valemetostat co‐administration caused a slight decrease in midazolam maximum plasma concentration ( C max ) (geometric least‐squares mean ratio [GMR], 0.966 [90% confidence interval (CI), 0.769–1.21]) and area under the plasma concentration–time curve up to the last quantifiable time (AUC last ) (GMR, 0.87 [90% CI, 0.75–1.03]), increased digoxin C max (GMR, 1.30 [90% CI, 1.07–1.57]), and AUC last (GMR, 1.27 [90% CI, 1.06–1.52]). The overall safety and efficacy outcomes were similar to other studies. Valemetostat showed a manageable and tolerable safety profile, without clinically meaningful DDI with sensitive CYP3A substrates. Co‐administration of valemetostat and P‐gp substrates with a narrow therapeutic index may require careful monitoring and/or DDI risk management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DigoxinMidazolamLymphoma, Non-HodgkinSulfonamidesHumansDrug InteractionsMaleMiddle AgedFemaleAgedAdultCytochrome P-450 CYP3AArea Under CurveTreatment OutcomeCytochrome P-450 CYP3A Inhibitors

Stichwörter der Autor:innen

drug–drug interactionshematologyinhibitorsmetabolismpharmacokinetics

Substanzen

DigoxinMidazolamCytochrome P-450 CYP3ASulfonamidesCytochrome P-450 CYP3A Inhibitors

Autor:innen und Institutionen

  • Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Yale University School of Medicine, New Haven, Connecticut, USA.
  • Emory University, Atlanta, Georgia, USA.
  • Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Masaya Tachibana, Steven Horwitz, Eric Jacobsen, Francine Foss, Pamela Allen, Pierluigi Porcu, Tatyana Feldman, Jia Ruan, Jonathan E Brammer, Jie Wang, Shinichi Inaba, Yuka Iko, Keiko Nakajima, Yasuyuki Kakurai, Noriaki Kitami, Yang Chen, Yvonne Lau

Förderung

  • NCI NIH HHS

Zitieren

APA

Tachibana, M., Horwitz, S., Jacobsen, E., Foss, F., Allen, P., Porcu, P., Feldman, T., Ruan, J., Brammer, J. E., Wang, J., Inaba, S., Iko, Y., Nakajima, K., Kakurai, Y., Kitami, N., Chen, Y., & Lau, Y. (2025). Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug–Drug Interaction Study in Patients With Non‐Hodgkin Lymphoma. Clinical and Translational Science. https://doi.org/10.1111/cts.70330

Vancouver

Tachibana M, Horwitz S, Jacobsen E, Foss F, Allen P, Porcu P, et al. Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug–Drug Interaction Study in Patients With Non‐Hodgkin Lymphoma. Clinical and Translational Science. 2025. doi:10.1111/cts.70330

BibTeX
@article{Tachibana2025,
  author = {Tachibana, Masaya and Horwitz, Steven and Jacobsen, Eric and Foss, Francine and Allen, Pamela and Porcu, Pierluigi and Feldman, Tatyana and Ruan, Jia and Brammer, Jonathan E and Wang, Jie and Inaba, Shinichi and Iko, Yuka and Nakajima, Keiko and Kakurai, Yasuyuki and Kitami, Noriaki and Chen, Yang and Lau, Yvonne},
  title = {Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug–Drug Interaction Study in Patients With Non‐Hodgkin Lymphoma},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70330}
}
Kostenlos starten →